Navigation Links
3SBio Inc. Appoints Mr. Bo Tan as Chief Financial Officer
Date:2/9/2009

SHENYANG, China, Feb. 9 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has appointed Mr. Bo Tan as Chief Financial Officer, effective February 1, 2009. Since joining 3SBio in October 2008, Mr. Tan has been acting as the financial advisor for the company, providing advice on the company's capital market initiatives and overseeing the company's treasury functions.

Dr. Jing Lou, Chief Executive Officer of 3SBio, commented, "I am delighted to name Bo as our CFO, given both his recent contributions to 3SBio as financial advisor and the broad wealth of experience he brings, as reflected by his previous roles in the financial services industry and pharmaceutical industry. I strongly believe that his skills and experience will further benefit our company during an important time of our development."

Mr. Tan, 36, has extensive experience within the financial and pharmaceutical industries, having worked across private equity, equity research and commercial practice. Previously, he has served as the Executive Director and a member of Investment Committee for Bohai Industrial Fund Management Company, a private equity fund in China. Earlier in his career, he spent six years in the pharmaceutical industry with Eli Lilly & Company and EMD Pharmaceuticals, Inc in North America and went on to serve as a China healthcare and consumer analyst at Lehman Brothers Asia and Macquarie Securities in Hong Kong.

"I am honored to be appointed as the CFO of 3SBio and I look forward to continuing to work closely with Dr. Lou and my other colleagues," remarked Mr. Tan. "Our company is in the middle of a critical and exciting stage of development, and I believe that my experiences will be able to contribute to what is an already strong management team."

Mr. Tan received his MBA degree from Thunderbird School of International Management, an MA degree in economics from the University of Connecticut and a BA degree in economics from Renmin University of China. Mr. Tan is also a CFA (Chartered Financial Analyst).

About 3SBio Inc.

3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. For more information, please visit 3SBio on the web at: http://www.3sbio.com .

    For more information, please contact:

     Bo Tan, CFO
     3SBio Inc.
     Tel: +86-24-2581-1820

     Investor Relations (China):
     Peter Schmidt
     FD Asia
     Tel: +86-10-8591-1953

     Investor Relations (US):
     Evan Smith or John Capodanno
     FD US
     Tel: +1-212-850-5600

'/>"/>
SOURCE 3SBio Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. 3SBio Inc. to Present at the Piper Jaffray 20th Annual Health Care Conference
2. 3SBio Inc. Announces Third Quarter 2008 Results
3. 3SBio Inc. Files for SFDA Approval of NuLeusin
4. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
5. 3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008
6. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
7. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
8. 3SBio Inc. Announces Results of Annual General Meeting
9. 3SBio Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference
10. 3SBio Inc. to Hold Annual General Meeting
11. 3SBio Inc. Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... 2017 , ... AxioMed president, Jake Lubinski, describes the AxioMed ... deformed, which is identical to how the human discs work to distribute force. ... to its natural state along a hysteresis curve, exactly like a healthy human ...
(Date:3/23/2017)... , March 23, 2017  SeraCare Life ... global in vitro diagnostics manufacturers and clinical ... industry,s first multiplexed Inherited Cancer reference ... by next-generation sequencing (NGS). The Seraseqâ„¢ Inherited ... with input from industry experts to validate ...
(Date:3/23/2017)... SEATTLE , March 23, 2017 ... translational development of novel therapies in immuno-oncology, today ... to lead" small molecule compounds that activate interferon ... (RLR) pathways and demonstrate immune-mediated tumor regression in ... in the study who demonstrated complete tumor regression ...
(Date:3/23/2017)... 23, 2017 In today,s pre-market ... in the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), ... MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." ... report at: ...
Breaking Biology Technology:
(Date:2/28/2017)... -- News solutions for biometrics, bag drop and New ... At ... 16 March, Materna will present its complete end-to-end passenger journey, ... a real benefit for passengers. To accelerate the whole passenger ... point solutions to take passengers through the complete integrated process ...
(Date:2/26/2017)... 2017  Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring, announces the appointment ... "Too often, too many offenders return to ... are trying to tackle this ongoing problem and ... family members. While significant steps are underway, Securus continues ...
(Date:2/21/2017)... and PORTLAND, Ore. , ... and the Avamere Family of Companies (Avamere Health Services, ... announced a six-month research study that will apply the ... eldercare at senior living and health centers. By analyzing ... hopes to gain insights into physical and environmental conditions, ...
Breaking Biology News(10 mins):